AJMC August 12, 2025
Jason Bergsbaken, PharmD, MBA, BCOP, highlights the growing role of real-world data in validating or de-implementing therapies, the need for vigilant postapproval outcomes monitoring, and the value of academic–community oncology partnerships.
At a recent Institute for Value-Based Medicine® event, Jason Bergsbaken, PharmD, MBA, BCOP, emphasized that real-world data are increasingly essential in pharmacy decision-making to both validate the adoption of new therapies and guide de-implementation when treatments fail to deliver expected value. Although randomized controlled trials remain the gold standard, he noted that accelerated FDA pathways can shorten premarket study periods, making postapproval surveillance critical. Bergsbaken, interim manager, oncology pharmacy at UW Health, and clinical assistant professor at the University of Wisconsin-Madison School of Pharmacy in Madison, urged vigilance, local...
Today's Sponsors
Today's Sponsor